SCHEMBL13089949

SCHEMBL13089949

N#Cc1cccc(-c2cc(N)c3cnccc3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.48
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
HTT P42858 1/20 0.47
RAD52 P43351 1/20 0.47
CHRNB2 P17787 1/20 0.45
CHRNA5 P30532 1/20 0.45
CHRNA4 P43681 1/20 0.45
CLK4 Q9HAZ1 1/20 0.44
ADORA2A P29274 2/20 0.44
MAP4K4 O95819 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.43
NEK1 Q96PY6 1/20 0.43
ADORA1 P30542 1/20 0.43
IDO1 P14902 1/20 0.43
GRM5 P41594 1/20 0.42
XDH P47989 1/20 0.41
GABRA1 P14867 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12327914 0.84 CYP11B1 (0.48) CYP17A1CYP11B1CYP11B2CHRNB2CHRNA5
SCHEMBL2431769 0.84 CHRNB2 (0.51) CYP17A1CYP11B1CYP11B2CHRNB2CHRNA5
SCHEMBL15172419 0.81 CYP11B1 (0.45) CYP17A1CYP11B1CYP11B2CHRNB2CHRNA5
SCHEMBL15172398 0.79 CYP11B2 (0.66) CYP17A1CYP11B1CYP11B2CHRNB2CHRNA5
SCHEMBL15172437 0.78 CYP11B1 (0.54) CYP17A1CYP11B1CYP11B2KDM4EPOLB
SCHEMBL15172418 0.77 PRKCZ (0.50) CYP17A1CYP11B1CYP11B2KDM4ECHRNB2
SCHEMBL3630922 0.77 SLC6A4 (0.41) CYP17A1CYP11B1CYP11B2CHRNB2CHRNA5
SCHEMBL13090021 0.76 HTR6 (0.51) CYP17A1CYP11B1CYP11B2CHRNB2CHRNA5
SCHEMBL2424122 0.75 IKBKB (0.45) CYP17A1CYP11B1CYP11B2KDM4ECHRNB2
SCHEMBL2424475 0.74 IKBKB (0.51) CYP17A1CYP11B1CYP11B2CLK4NEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366699-B1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2013-08-07 EP disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 CYP17A1 777/4885CYP11B1 353/4885CYP11B2 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.